Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III trial of Hengli botulinum toxin type A injection for lower limb spasticity after stroke in adults
CTR20240489Phase 3Active
- Sponsor
- Lanzhou Biotechnology Development
- Start
- Mar 2024
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 3 trial of lanbotulinumtoxin-A in poststroke spasticity (PSS), sponsored by Lanzhou Biotechnology Development. Started Mar 2024; status: active.
02
Drugs
lanbotulinumtoxin-A
03
Conditions
poststroke spasticity (PSS)
Beyond the preview
Go deeper on CTR20240489.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20240489.